Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYBRIDGE
NCT05652686Phase 2Recruiting
- Sponsor
- Phanes Therapeutics, Inc.
- Start
- Sep 2023
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of peluntamig in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), neuroendocrine prostate cancer (NEPC), gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), neuroendocrine carcinoma (NEC), sponsored by Phanes Therapeutics, Inc.. Started Sep 2023; status: recruiting.
02
Drugs
peluntamig
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)neuroendocrine prostate cancer (NEPC)gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT05652686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652686.